DOI: https://dx.doi.org/10.18203/issn.2455-4510.IntJResOrthop20221626
Published: 2022-06-24

A cross-sectional survey of Indian orthopaedicians to understand the place in therapy for the latest soft gel formulation of etoricoxib

Sagar Karvir, Sameer S. Jadhwar, Kapil Dev Mehta

Abstract


Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for arthritis (RA), osteoarthritis (OA), low back pain (LBP) and other musculoskeletal disorders. Novel formulations such as soft gel formulations are being introduced for NSAIDs in place of the traditional tablet formulation. The objective of this study was to quantify orthopaedicians insights for the recently available soft gel formulation of Etoricoxib.

Methods: The questions for the survey instrument (Google forms) were developed by researchers upon review of scientific literature and subsequent discussions with practicing orthopaedicians. This was a cross-sectional digital survey involving 506 orthopaedicians across India via online responses collated via Google forms.

Results: 81.4% doctors agreed that etoricoxib soft gel capsules are faster acting than the tablet formulation, whereas 89.6% of the doctors agree/strongly agreed that etoricoxib soft gel capsules would have better compliance because of its bitter taste masking ability. More than 96% doctors acknowledged that etoricoxib soft gel capsule’s characteristics such as higher drug dissolution and absorption would benefit their patients more than the etoricoxib tablet formulation.

Conclusions: Given its advantages, the etoricoxib soft gel formulation, in the days to come, could be one of the preferred options for the management of pain and other arthritic conditions for patients in India.


Keywords


Etoricoxib, NSAIDs, Osteoarthritis, Soft gel capsules

Full Text:

PDF

References


Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol. 2009;44(19):44-52.

Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213-22.

Johnson RE, Hornbrook MC, Hooker RS, Woodson GT, Shneidman R. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation. Pharmacoeconomics. 1997;12:76-88.

Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl. 1998;51:8-16.

White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999;15:445-58.

Tramèr MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000;85:169-82.

Dallob. Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. J Clin Pharmacol 2003;43:573-85.

Irvine J. Formulation and delivery strategies of ibuprofen: challenges and opportunities. Drug Dev Ind Pharm. 2018;44(2):173-83.

Singh I, Kaur B, Kumar P, Arora S. Masking the unpleasant taste of etoricoxib by crosslinked acrylic polymer based ion-exchange resin complexation. Polim Med. 2010;40(3):19-26.

Prasad V. Formulation and modifying drug release from hard and soft gelatin capsules for oral drug delivery. Int J Res Develo Pharm Life Sci. 2017;6(4):2663-77.

Lawati HA, Jamali F. (2016). Onset of action and efficacy of ibuprofen liquigel as compared to solid tablets: a systematic review and meta-analysis. J Pharm Pharmaceut Sci. 2016;19(3):301-11.

Patra S, Samantaray R, Pattnaik S, Barik BB. Taste masking of etoricoxib by using ion-exchange resin. Pharmaceut Develop Technol. 2010;15(5):511-7.

Lodha A. Formulation and evaluation of transparent ibuprofen soft gelatin capsule. Journal of pharmacy & bioallied sciences. 2021;4(1):S95-7.

American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the initial evaluation of the adult patient with acute musculoskeletal symptoms. Arthritis Rheum. 1996;39:1-8

Brooks. Etoricoxib for arthritis and pain management Ther Clin Risk Manag. 2006;2(1):45-57.

Zacher. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis Curr Med Res Opin. 2003;19(8):725-36.

Baraf. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial J Rheumatol. 2007;34(2):408-20.